A Phase 1, Open Label, Single-dose 3-way Crossover Study To Evaluate The Relative Bioavailability Of A Solid Dose Formulation Of Pf-06651600 Under Fasting Conditions And The Effect Of A High Fat Meal On The Bioavailability Of The Solid Dosage Formulation Of Pf-06651600 In Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 20 Jun 2016
At a glance
- Drugs PF 6651600 (Primary) ; PF 6651600 (Primary)
- Indications Crohn's disease
- Focus Pharmacokinetics
- Sponsors Pfizer
- 14 Jun 2016 Status changed from active, no longer recruiting to completed.
- 16 May 2016 Status changed from recruiting to active, no longer recruiting.
- 31 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 May 2016, according to ClinicalTrials.gov record.